Literature DB >> 16330882

Proteinuria and fusion of podocyte foot processes in rats after infusion of cytokine from patients with idiopathic minimal lesion nephrotic syndrome.

Eduardo H Garin1, Paul F Laflam, Karl Muffly.   

Abstract

BACKGROUND/AIMS: We report on the isolation of a factor secreted by peripheral blood mononuclear cells from patients with idiopathic minimal lesion nephrotic syndrome (IMLNS) in relapse and its effect on proteinuria and podocyte morphology in the rat.
METHODS: Peripheral blood mononuclear cells from patients with IMLNS (in relapse and in remission) and patients with focal segmental glomerulosclerosis were cultured for 72 h. Supernatants from 20 x 10(6) cultured cells were separated by liquid chromatography into three fractions according to markers (bovine serum albumin, beta-amylase, and apoferritin). Each supernatant fraction was infused into rats for 5 days using an osmotic pump. Proteinuria, 24-hour albumin excretion or albumin/creatinine ratio in a 24-hour urine collection, was measured daily starting 3 days prior to fraction infusion. Renal tissue was obtained for electron microscopy studies. The beta-amylase fraction underwent electrophoresis using isoelectric focusing gel.
RESULTS: When protein excretion was compared prior to and during supernatant fraction infusion, a significant increase in proteinuria was observed only when beta-amylase fraction from IMLNS patients in relapse was infused (p < 0.05). Protein electrophoresis of the beta-amylase fraction showed a single band at pH 6.0 only in samples from IMLNS patients in relapse. The band was composed of two proteins, beta-amylase and a 100-kDa glycoprotein. Fusion of foot processes was observed only when the beta-amylase fraction from IMLNS patients in relapse was infused.
CONCLUSIONS: The infusion of the beta-amylase fraction containing a 100-kDa glycoprotein from IMLNS patients in relapse induced proteinuria and effacement of foot processes in the rat. This protein may play a role in the pathogenesis of IMLNS. 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330882     DOI: 10.1159/000089689

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  5 in total

1.  T regulatory cell function in idiopathic minimal lesion nephrotic syndrome.

Authors:  Carlos Araya; Leila Diaz; Clive Wasserfall; Mark Atkinson; Wei Mu; Richard Johnson; Eduardo Garin
Journal:  Pediatr Nephrol       Date:  2009-06-03       Impact factor: 3.714

2.  Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome.

Authors:  Delma Veron; Kimberly Reidy; Arnaud Marlier; Claudia Bertuccio; Guillermo Villegas; Juan Jimenez; Michael Kashgarian; Alda Tufro
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

3.  T-cell receptor diversity in minimal change disease in the NEPTUNE study.

Authors:  Shiying Liu; William S Bush; Kristy Miskimen; Agustin Gonzalez-Vicente; Jessica N Cooke Bailey; Ioanna Konidari; Jacob L McCauley; John R Sedor; John F O'Toole; Dana C Crawford
Journal:  Pediatr Nephrol       Date:  2022-08-09       Impact factor: 3.651

4.  Polymorphisms in interleukin-4-related genes in patients with minimal change nephrotic syndrome.

Authors:  Yuka Ikeuchi; Yasuko Kobayashi; Hirokazu Arakawa; Michiko Suzuki; Kazushi Tamra; Akihiro Morikawa
Journal:  Pediatr Nephrol       Date:  2008-11-15       Impact factor: 3.714

5.  Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes.

Authors:  Takuji Ishimoto; Gabriel Cara-Fuentes; Heiman Wang; Michiko Shimada; Clive H Wasserfall; William E Winter; Christopher J Rivard; Carlos E Araya; Moin A Saleem; Peter W Mathieson; Richard J Johnson; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2013-05-21       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.